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Abstract
Purpose To assess the efficacy of glaucoma drainage devices (GDD) in uveitic glaucoma and non-uveitic glaucoma, and to
perform a meta-analysis of previously published results to compare with our data.
Methods Retrospective case-control study, in which all eyes that underwent GDD surgery were included from 2015 onwards.
Cases were defined as patients with uveitic glaucoma. Patients with non-uveitic glaucoma served as controls. To compare our
results, a review of the literature was performed using PubMed database.
Results A total of 99 eyes were included (38 with uveitic glaucoma). The preoperative IOP was 25.9 ± 7.7 mmHg and 27.9 ±
9.6 mmHg for patients with and without uveitis (p = 0.277). No significant differences were found between patients with and
without uveitis in the final IOP or reduction in IOP (44.9% vs. 42.8%, respectively). Within the first year after surgery, 13.2% of
cases developed macular edema (vs. 6.6%; p = 0.267) and 15.8% a transient hypotony (vs. 8.2%; p = 0.242). A meta-analysis of
24 studies showed a postoperative weighted mean difference of − 17.8 mmHg and 2.2 lower number of IOP-lowering medica-
tions in uveitic glaucoma (compared to − 13.2 mmHg and 3.5 in the current study, respectively).
Conclusion GDD surgery in patients with uveitis has a similar effect on IOP as in patients without uveitis. The risks of developing
macular edema and hypotony were slightly higher in patients with uveitis, but the results were not statistically significant. These
findings are in line with previous reports, though data on the efficacy of GDD surgery and macular edema in uveitic glaucoma is
scarce.
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Introduction
Glaucoma, aneurodegenerative eyedisease, is themost com-
mon cause of irreversible blindness worldwide. Of all differ-
ent forms of glaucoma, about 20–30% are caused by an un-
derlying systemic or ophthalmic disorder: secondary glauco-
ma [1]. One of the most serious causes is uveitis, especially
anterior uveitis [2]. The incidence of secondary glaucoma
caused by uveitis (uveitic glaucoma) is reported to be 10–
20% [3]. Patientswith both glaucoma and uveitis have a high
risk of severe visual impairment [2, 4]. Uveitic glaucoma
presents a two-pronged problem: inflammatory damage to
the trabecular meshwork and uvea (e.g., synechiae) coupled
with steroid-induced increase in intraocular pressure (IOP).
It is one of the most difficult forms of glaucoma to manage,
because the ophthalmologist must simultaneously address
inflammation and elevated IOP. Among the current surgical
treatment options are trabeculectomy, deep sclerectomy,
minimally invasive glaucoma surgery (MIGS; e.g.,
trabectome), cyclodestructive procedures, and several types
of glaucoma drainage devices (GDD), with comparable effi-
cacy [5–7].However, the long-term roleof trabeculectomy in
patients with uveitis is compromised by young age,
inflammation-induced fibrosis and conjunctival scarring,
and scleral thinning, making trabeculectomy in many cases
not the optimal choice. Moreover, uveitic glaucoma usually
develops at a younger age (having a thick Tenon’s capsule
and more robust healing response, often resulting in
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progressive subconjunctival fibrosis) than primary glauco-
ma. Cyclodestructive procedures are irreversible; hence, this
treatment option is often reserved for eyeswith aworsevisual
prognosis. Therefore, GDD are currently considered a better
choice in the treatment of uveitic glaucoma. The most com-
monly used GDD are the valved Ahmed and the non-valved
Baerveldt implant. Nonetheless, reports on the performance
of these GDD in uveitis eyes are scarce. Therefore, we com-
pared the efficacy and safety of the most common GDD
(Ahmed and Baerveldt implant) in eyes with uveitic glauco-
ma to glaucoma eyes without uveitis. Next, we assessed the
differences in complications after GDD surgery. Finally, we
performed a review of the literature on these GDD (Ahmed
FP7 andBaerveldt-350) in eyeswith uveitic glaucoma and in
eyes with other forms of glaucoma. Meta-analyses of the




The first part of the study was designed as a retrospective
study and the second part as a review with several meta-
analyses (see further). For the retrospective study, we selected
all patients that underwent at least one GDD surgery in the
period from January 2015 to January 2018 at the Department
of Ophthalmology of the Erasmus University Medical Center,
Rotterdam, The Netherlands.
All patients underwent extensive ophthalmic examination
at each visit. The medical records of all patients were
reviewed, and clinically relevant data were entered in a data-
base. Data of the last preoperative visit, postoperative follow-
up data at 1 day, 1 week, 1 month (monthly till 6 months),
1 year, and their last visit were collected. The following data
were recorded: age, gender, ethnicity, medical history, visual
acuity, refraction, intraocular lens status, IOP, type of uveitis,
complications of surgery, use of medication, date of surgery,
operated eye, and type of GDD. Eyes that had previously
failed GDD surgery were excluded.
Surgical technique
All GDD surgeries were performed by the same surgeon (RW)
using the following surgical technique. A limbal-based con-
junctival flap was made in the superotemporal quadrant. An
Ahmed FP7 (New World Medical, Rancho Cucamonga, CA,
USA) or a Baerveldt BG101-350 (Abbott Medical Optics Inc.,
Santa Ana, CA, USA) GDD was placed 10 mm from the
limbus, the Baerveldt with its wings underneath the lateral
and superior rectus muscles. The plate was secured to the
sclera with two nylon 9-0 sutures. The anterior chamber was
entered using a 23 g knife after which the tube was inserted,
with a preferred intraocular tube length of 3 mm. Next, the
tube was sutured to the sclera with one nylon 9-0 suture and,
in case of a Baerveldt GDD, tied off with a vicryl 6-0 suture.
The extraocular part of the tube was patched with fascia lata
(Tutoplast; Tutogen Medical, USA). Finally, the conjunctiva
was closed with a running vicryl 8-0 suture.
The main reason for preferring an Ahmed GDD to a
Baerveldt GDD were cases in which a quick postoperative
IOP-lowering effect was required. At the time of surgery, there
was no active inflammation. Postoperative topical medication
(steroids and antibiotics) was similar for both GDD. Patients
that were on preoperative immunosuppressive medications
and/or antibiotic or antiviral systemic medications continued
their use postoperatively at the discretion of the uveitis spe-
cialist (AR), who controlled the uveitis regularly during fol-
low-up. If postoperative necessary glaucoma medication was
added to reach target IOP.
Assessment of main outcomes
The IOP was measured using Goldmann applanation tonom-
etry (Haag-Streit, Köniz, Switzerland). The device had been
calibrated according to manufacturer’s recommendations. The
number of IOP-lowering medications was calculated by
adding the number of different categories of medication. The
categories were beta-blockers, prostaglandin-analogues, car-
bonic anhydrase inhibitors, alfa2-agonists, and oral acetazol-
amide. Fixed combinations of eye drops were calculated as
two separate drugs. Patients with an unexplained decrease of
visual acuity postoperatively underwent optical coherence to-
mography (OCT) of the macular region using Spectralis OCT
(Heidelberg Engineering, Dossenheim, Germany) to detect
underlying macular edema. Hypotony was defined as an IOP
below 5 mmHg at two or more consecutive visits during the
first year of follow-up.
Search strategy and data extraction of studies
For the second part of the study, a review of the literature was
performed by searching the PubMed database for studies on
the Ahmed FP7 or Baerveldt-350 GDD up to April 2018.
Studies had to assess the performance of at least one or both
GDD on the IOP in either uveitic glaucoma or a mixture of
different types of glaucoma. If a study used another type of
Ahmed or Baerveldt GDD, the study was excluded from the
meta-analyses. Extracted data included the first author, publi-
cation year, study design, sample size, diagnosis, type of
GDD, follow-up duration, pre- and post-operative IOP, num-
ber of IOP-lowering medications pre- and postoperative, num-
ber of patients without any IOP-lowering medications at fol-
low-up, number of secondary surgeries, and occurrence of
macular edema or hypotony. From the research groups that
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published the results of the same study population more than
once (e.g., 3-year follow-up and 5-year follow-up), only one
study was included.
Statistical analyses
Differences in general baseline characteristics of the patients
were analyzed using independent t tests for continuous vari-
ables and chi-square tests for categorical variables. Within
group analyses (e.g., between pre- and postoperative IOP)
were analyzed using paired t tests.
Linear mixed models were applied to assess differences in
IOP and IOP-lowering medication over time. Thus, two
models were created in which one of these variables was fitted
as the dependent variable with (fixed) visit as a factor, assum-
ing a random effects intercept, and an unstructured correlation
matrix. The models were adjusted for age, gender, type of
GDD, and presence of uveitis. Follow-up time was calculated
as the time between the date of surgery and the date of the last
visit. If an eye required a second surgery during follow-up,
follow-up was counted until the date of the second surgery to
minimize confounding. All statistical analyses were per-
formed using SPSS v22.0 for Windows (SPSS Inc.,
Chicago, IL, USA) and R statistical package version 2.11.1
for Mac (http://www.r-project.org). A p value of < 0.05 was
considered statistically significant.
Data analysis of the literature review was performed using
RevMan 5 for Windows (The Cochrane Collaboration,
Oxford, UK). The mean and standard deviation were used to
calculate the weighted mean differences (WMDs) with corre-
sponding 95% confidence interval (CI). Heterogeneity was
evaluated by calculating the I2-statistics and p values [8]. If
heterogeneity was high (I2 > 50%), the studies that created the
heterogeneity were excluded. This was done by sequentially
omitting one study and reanalyzing the estimates of the re-
maining studies [9]. Results were pooled using the random-
effects model in a meta-analysis. Using this method, the
WMD of IOP across the retrieved studies was calculated for
four groups: Ahmed GDD, Baerveldt GDD, both GDD
in uveitic glaucoma, and in a mixture of different types of
glaucoma. This approachwas also applied to analyze the num-
ber of IOP-lowering medications.
Results
A total of 99 eyes (86 patients) were included (38 with uveitic
glaucoma). Of the patients with uveitic glaucoma, 44.7% had
anterior uveitis, 2.6% had intermediate uveitis, 13.2% had
posterior uveitis, and the remaining 39.4% had panuveitis.
Table 1 shows the baseline characteristics of the study popu-
lation and the underlying cause of the uveitis. Patients with
uveitic glaucoma were significantly younger, more often
female, and had a higher number of IOP-loweringmedications
compared to patients with non-uveitic glaucoma. Almost half
of the patients had a history of intraocular surgery, most often
cataract surgery (52.6% of the uveitic glaucoma eyes and
69.6% of the non-uveitic glaucoma eyes). The duration be-
tween the first episode of the uveitis and the first glaucoma
surgery was median (interquartile range) 4.0 (2–7) years.
Figure 1 displays the IOP levels (separately for Ahmed
GDD and Baerveldt GDD) and number of IOP-lowering med-
ications for the whole study population during follow-up.
Nine eyes underwent a second surgery within the first year
after the GDD surgery. Of these, one had uveitic glaucoma
and underwent regular cataract extraction. The remaining
(eight) had non-uveitic glaucoma of which one underwent
regular trans pars plana vitrectomy, one developed
neovascular glaucoma for which cyclocryotherapy was ap-
plied, and six required GDD-related surgery because of tube
malposition (N = 2), tube protrusion through the conjunctiva
(N = 1), tube removal (persistent hypotony; N = 2), and tube
flushing (N = 1). As we included two different GDD (Ahmed
and Baerveldt), we first assessed whether there were differ-
ences in the results between both GDD. None of the in Table 1
presented baseline characteristics were significantly different
between both GDD, except for the preoperative number of
IOP-lowering medications (4.14 ± 1.36 and 3.50 ± 1.21 [p =
0.015] for the Ahmed GDD and Baerveldt GDD, respective-
ly). The IOP in the AhmedGDD group decreased from 27.5 ±
9.1 mmHg preoperative to 14.5 ± 4.5 mmHg (p < 0.001; N =
43) at the last follow-up, and in the Baerveldt GDD group
from 26.9 ± 8.9 mmHg to 12.1 ± 3.8 mmHg (p < 0.001; N =
56). Figure 1 also shows that in the very early postoperative
phase, the IOP was significantly lower with an Ahmed GDD
compared to a Baerveldt GDD; however, at 6 months, this
changed to a significantly higher IOP (p = 0.031). Also at
the last visit (> 1 year postoperative), eyes with an Ahmed
GDD had still a significantly higher IOP compared to the
Baerveldt GDD (p = 0.005). The only significant difference
in number of IOP-lowering medications during follow-up was
at 1 month postoperative (1.14 ± 1.25 and 1.96 ± 1.74 [p =
0.010] for the Ahmed GDD and Baerveldt GDD, respective-
ly). Because of the comparable performance of both GDD on
the IOP, we combined both GDD into one group with uveitic
glaucoma and one with non-uveitic glaucoma. As expected,
the IOP decreased significantly after GDD surgery in eyes
with uveitic glaucoma from 25.9 ± 7.7 to 12.7 ± 4.4 mmHg
(44.9% decrease; p < 0.001), and in eyes with non-uveitic
glaucoma from 27.9 ± 9.6 to 13.3 ± 4.2 mmHg (42.8% de-
crease; p < 0.001). The postoperative decrease in IOP in eyes
with uveitic glaucoma did not differ with the decrease in IOP in
eyes with non-uveitic glaucoma (p = 0.729). If we take the IOP
of the whole follow-up period into account, the linear mixed
model showed that age and uveitis were significantly associated
with IOP during follow-up. The presence of uveitis was
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associated with a 1.93mmHg lower IOP over time compared to
eyes without uveitis (p = 0.008). The number of IOP-lowering
medications was not significantly different between eyes with
and without uveitis during follow-up. Approximately 70% of
eyes did not have to use any IOP-lowering medication after
6 months of GDD surgery (Fig. 1). At the last follow-up, the
mean ± standard deviation number of IOP-lowering medica-
tions was similar for the uveitic and non-uveitic glaucoma eyes
(0.76 ± 1.34 and 0.92 ± 1.33, respectively; p = 0.576).
Macular edema developed in 13.2% of eyes with uveitic
glaucoma (vs. 6.6%; p = 0.267) and hypotony in 15.8% (vs.
8.2%;p= 0.242). Inbothgroups, thevisual acuityand spherical
equivalent did not change significantly during follow-up.Also,
at the end of follow-up, the visual acuity did not differ between
eyes with uveitic and non-uveitic glaucoma (p = 0.317).
The literature search yielded a total of 24 studies that
assessed the performance of the Ahmed FP7 or Baerveldt-
350 GDD (Table S1) [10–33]. Most studies analyzed a mix-
ture of different types of glaucoma. In uveitic glaucoma, 6–
65% of eyes did not have to use any IOP-lowering medication
postoperative (compared to 3–83% in the glaucoma mixture
studies), postoperative macular edema developed in 2–26%
(compared to 2–4% in the glaucoma mixture studies), and
hypotony was reported to be present in 0–36% (compared to
1–37% in the glaucoma mixture studies). However, postoper-
ative macular edema was assessed in only six studies.
Of the 24 retrieved studies, 10 were excluded from the
meta-analyses for IOP and 11 were excluded from the meta-
analyses for IOP-lowering medication because of missing da-
ta. Figures 2 and 3 present the results of the meta-analyses for
Table 1 Baseline preoperative
characteristics of the study
population presented as mean ±
standard deviation unless stated
otherwise
Uveitic glaucoma
(N = 38 eyes)
Non-uveitic glaucoma
(N = 61 eyes)
p value
Age (years)a 44.4 ± 18.3 59.9 ± 19.3 < 0.001
Gender, female (N, %)a 24 (75.0) 28 (51.9) 0.034
Caucasian descent (N, %)a 22 (68.8) 40 (74.1) 0.595
IOP (mmHg) 25.9 ± 7.7 27.9 ± 9.6 0.277
Number of IOP-lowering Rx 4.24 ± 1.19 3.49 ± 1.30 0.005
Visual acuity 0.63 ± 0.38 0.50 ± 0.36 0.107
Spherical equivalent (D)b − 1.46 ± 3.97 − 0.59 ± 2.99 0.436
Follow-up till censored (months) 13.0 ± 8.7 13.8 ± 9.3 0.686
Previous eye surgery (N, %)c 19 (50.0) 23 (37.7) 0.229





Associated systemic disease NA
Arthritis psoriatica 1 (2.6)
Behcet 1 (2.6)
HLA-B27 positive 1 (2.6)
JIA 3 (7.9)
Sarcoidosis 7 (18.4)
Systemic sclerosis 1 (2.6)
Clinical ocular syndromes NA
Birdshot chorioretinopathy 2 (5.3)
FHUS (negative for viruses) 1 (2.6)
Idiopathic NA
Quantiferron positive 5 (13.2)
Quantiferron negative/e.c.i. 11 (28.9)
NA not applicable/available, IOP intraocular pressure, FHUS Fuchs heterochromic uveitis syndrome, JIA juvenile
idiopathic arthritis, TBC tuberculosis, HSV herpes simplex virus, VZV varicella zoster virus
a Data per patient instead of per eye
b Excluding eyes that underwent cataract surgery
c Including surgery for glaucoma (N = 8), cataract (N = 26), trans pars plana vitrectomy (N = 2), cornea transplants
(N = 3), and other (N = 3)
Graefes Arch Clin Exp Ophthalmol
the performance of the Ahmed FP7, the Baerveldt-350, both
GDD in uveitic glaucoma, and both GDD in a mixture of
different types of glaucoma, on the IOP and IOP-lowering
medication, respectively. In all analyses, substantial heteroge-
neity was present. However, after omitting the studies that
contributed to the heterogeneity, the results did not change
significantly. The WMD [95% CI] (I2) for IOP (in mmHg)
were 15.96 [14.67–17.25] (0%), 18.69 [17.32–20.07] (44%),
17.76 [15.43–20.08] (29%), and 17.77 [16.42–19.11] (38%),
respectively. For IOP-lowering medication, the WMD [95%
CI] (I2) were 1.80 [1.51–2.09] (34%), 2.11 [1.93–2.29] (49%),
2.21 [1.94–2.48] (26%), and 2.02 [1.83–2.21] (48%),
respectively.
In our study population, eyes with uveitic glaucoma had a
mean difference in IOP of 13.18 mmHg and in IOP-lowering
medications of 3.47.
Discussion
The efficacy of GDD in uveitic vs. non-uveitic glaucoma in a
tertiary center was presented and compared with the literature
by performing several meta-analyses. The results of GDD
surgery in eyes with uveitic glaucoma are similar to those of
eyes with non-uveitic glaucoma. Both groups showed a
decrease in IOP of ~ 42% after GDD surgery. Although eyes
with uveitic glaucoma developed more often macular edema
and hypotony compared to eyes with non-uveitic glaucoma,
the difference was not statistically significant.
There are not many studies that compared the performance
of GDD in patients with and without uveitic glaucoma. Most
studies analyzed a mixture of different types of glaucoma
making it hard to compare our results. Our literature search
identified four prospective randomized controlled trials on
either the Ahmed FP7 or Baerveldt-350 GDD. Nonetheless,
all studies on the efficacy of GDD in uveitic glaucoma were
retrospective studies. None of the 24 identified studies
assessed the difference of GDD between patients with and
without uveitis, except for one [14]. Nevertheless, that study
only included the Ahmed FP7 and not the Baerveldt-350.
Furthermore, their sample size (N = 15) was very small. Our
finding that the decrease in IOP after GDD surgery is similar
in eyes with and without uveitis is in agreement with their
results [14]. In contrast to the current study, they reported an
increase in number of IOP-lowering medications 1-month
postoperatively. This increase was higher in open-angle glau-
coma eyes compared to uveitic glaucoma eyes, and IOP-
lowering medications became stable at 2 years postoperative
[14]. However, the number of postoperative IOP-lowering
medications was highest in their study (2.6 in uveitic
Fig. 1 Mean intraocular pressure (IOP; lines) and number of IOP-
lowering medications (bars) during follow-up for non-uveitic glaucoma
treated with the Ahmed FP7 glaucoma drainage device (GDD; solid black
line; black bar), non-uveitic glaucoma treated with Baerveldt-350 GDD
(dotted black line; light gray bar), uveitic glaucoma treated with Ahmed
FP7 GDD (solid gray line; black bar), and uveitic glaucoma treated with
Baerveldt-350 GDD (dotted gray line; white bar)
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glaucoma and 2.8 in non-uveitic glaucoma) among all re-
trieved studies. It should be noted that in the current study,
the mean IOP at baseline was lower compared to other studies,
but this might be related to the higher number of IOP-lowering
medications used by our patients (Fig. 3C, D). The non-
significant difference in IOP between uveitic glaucoma and
other forms of glaucoma may also be observed from the re-
sults of the meta-analyses (Fig. 2C, D).
Our proportion of eyes requiring secondary surgery related to
the GDD (6.1%) is similar to other studies reporting 0–13%
(Table S1). Due to the retrospective design of most studies, the
development of macular edema may have been underreported.
Nevertheless, according to our results and the previous reports
(Table S1), it is likely that the risk of developing macular edema
after GDD surgery is higher in uveitic glaucoma compared to
non-uveitic glaucoma. The development of (transient) hypotony
in our study (15.8% in uveitic glaucoma and 8.2% in non-uveitic
glaucoma) is in agreement with others; however, the reported
range in other studies is extremely wide: 0–37.1% (Table S1).
One of the strengths of the current study is that the perfor-
mance of the GDD did not depend on the great variability in
how glaucoma specialists perform GDD surgery, because all
surgeries were performed by the same surgeon using the same
technique each time. Also, the indication for surgery was set
Fig. 2 Meta-analyses for the postoperative change in IOP after the Ahmed FP7 (A), Baerveldt-350 (B), both GDD in uveitic glaucoma (C), and both
GDD in a mixture of different types of glaucoma (D)
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by the same surgeon. To minimize the effect of different GDD
on the IOP, only two types of GDD were included.
Furthermore, the IOP was measured at each visit using the
same method.
Fig. 3 Meta-analyses for the postoperative change in number of IOP-lowering medications after the Ahmed FP7 (A), Baerveldt-350 (B), both GDD in
uveitic glaucoma (C), and both GDD in a mixture of different types of glaucoma (D)
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Due to the retrospective design of the current study, there
are several limitations. First, the follow-up of our study was
relatively short. Nevertheless, according to the tube versus
trabeculectomy study, the IOP of the Baerveldt GDD did not
change between 1-year follow-up and 5-year follow-up [31].
Moreover, the Ahmed Baerveldt Comparison study and
Ahmed versus Baerveldt study did not show significant dif-
ferences in IOP after 6 months [28, 30]. The study that com-
pared the Ahmed GDD efficacy in uveitic glaucoma to open-
angle glaucoma patients had a longer follow-up than the cur-
rent study, but their results on IOP did not change significantly
after 3 months of follow-up [14]. Second, our differences be-
tween Ahmed GDD and Baerveldt GDD may suffer from
selection bias, because the surgeon may have a preference
for a certain GDD in specific situations. For example, the
higher drop in IOP in the first week after AhmedGDD surgery
(compared to Baerveldt GDD; Fig. 1) may result from this
selection bias next to the valve mechanism. However, the
significantly higher IOP after Ahmed GDD surgery compared
to Baerveldt GDD at the end of follow-up is in agreement with
two other studies that compared the Ahmed FP7 with the
Baerveldt-350 GDD [28, 30]. Moreover, the preoperative
IOP level did not differ between Ahmed GDD and Baerveldt
GDD (p = 0.660; Fig. 1), suggesting that selection bias based
on the preoperative IOP played a minor role. Regarding the
meta-analyses, if different types of non-uveitic glaucoma
would result in different outcomes of GDD surgery, caution
should be taken when interpreting the studies including a mix-
ture of types of glaucoma. The heterogeneity between studies
may also be explained by the many different factors that may
affect postoperative GDD results (e.g., experience of surgeon,
surgical technique, follow-up duration, IOP measurement
methods, method used to calculate number of IOP-lowering
medications, severity of glaucoma, etc.).
The risk of developing secondary glaucoma due to uveitis
depends on various factors such as the age, ethnicity, duration
of inflammation, the clinical manifestations of uveitis, and its
therapy. High risk for glaucoma development was especially
noted for viral causes and anterior location of uveitis [34]. Our
results are consistent with these findings, as the majority of
our patients exhibited anterior segment involvement of
uveitis.
In conclusion, both the Ahmed FP7 and the Baerveldt-350
GDD are effective in lowering IOP in uveitic glaucoma. Their
performance in terms of IOP and IOP-lowering medications is
similar to eyes with non-uveitic glaucoma. Also, the risk of
developing macular edema or hypotony after GDD was not
different in uveitic glaucoma compared to non-uveitic glauco-
ma. Unfortunately, prospective studies that assessed the clin-
ical manifestations of uveitis in relation to GDD surgery are
currently lacking. Future prospective randomized controlled
trials on uveitic glaucoma are required to verify the current
results.
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